Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy HOOKIPA Pharma stock | $10.89

Own HOOKIPA Pharma stock in just a few minutes.

Fact checked

HOOKIPA Pharma Inc is a biotechnology business based in the US. HOOKIPA Pharma shares (HOOK) are listed on the NASDAQ and all prices are listed in US Dollars. HOOKIPA Pharma employs 85 staff and has a trailing 12-month revenue of around USD$18 million.

How to buy shares in HOOKIPA Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for HOOKIPA Pharma. Find the stock by name or ticker symbol: HOOK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until HOOKIPA Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$10.89, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of HOOKIPA Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of HOOKIPA Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

HOOKIPA Pharma share price

Use our graph to track the performance of HOOK stocks over time.

HOOKIPA Pharma shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$10.89
52-week rangeUSD$5.8 - USD$14.3662
50-day moving average USD$11.5427
200-day moving average USD$10.5804
Wall St. target priceUSD$21.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.914

Buy HOOKIPA Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy HOOKIPA Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HOOKIPA Pharma price performance over time

Historical closes compared with the close of $10.89 from 2021-01-11

1 week (2021-01-07) -1.89%
1 month (2020-12-17) -7.24%
3 months (2020-10-16) 11.46%
6 months (2020-07-17) -4.05%
1 year (2020-01-17) -2.68%
2 years (2019-01-13) N/A
3 years (2018-01-13) N/A
5 years (2016-01-13) N/A

HOOKIPA Pharma financials

Revenue TTM USD$18 million
Gross profit TTM USD$-34,370,000
Return on assets TTM -23.47%
Return on equity TTM -38.41%
Profit margin -232.01%
Book value $3.592
Market capitalisation USD$352.9 million

TTM: trailing 12 months

Shorting HOOKIPA Pharma shares

There are currently 1.2 million HOOKIPA Pharma shares held short by investors – that's known as HOOKIPA Pharma's "short interest". This figure is 30.9% up from 892,636 last month.

There are a few different ways that this level of interest in shorting HOOKIPA Pharma shares can be evaluated.

HOOKIPA Pharma's "short interest ratio" (SIR)

HOOKIPA Pharma's "short interest ratio" (SIR) is the quantity of HOOKIPA Pharma shares currently shorted divided by the average quantity of HOOKIPA Pharma shares traded daily (recently around 153782.23684211). HOOKIPA Pharma's SIR currently stands at 7.6. In other words for every 100,000 HOOKIPA Pharma shares traded daily on the market, roughly 7600 shares are currently held short.

However HOOKIPA Pharma's short interest can also be evaluated against the total number of HOOKIPA Pharma shares, or, against the total number of tradable HOOKIPA Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HOOKIPA Pharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 HOOKIPA Pharma shares in existence, roughly 40 shares are currently held short) or 0.0607% of the tradable shares (for every 100,000 tradable HOOKIPA Pharma shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against HOOKIPA Pharma.

Find out more about how you can short HOOKIPA Pharma stock.

HOOKIPA Pharma share dividends

We're not expecting HOOKIPA Pharma to pay a dividend over the next 12 months.

HOOKIPA Pharma overview

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site